New Weight-Loss drug SA030 enters first human safety trial
NCT ID NCT07479862
First seen Mar 22, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study is the first time the experimental drug SA030 is being tested in people. It aims to check the safety and how the body handles a single dose in 40 overweight or obese adults aged 18 to 55. Participants will be randomly assigned to receive either SA030 or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd North Terrace
Adelaide, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.